Aakaar Medical Technologies SME: Check IPO Date, Live Subscription and Key Details
Aakaar Medical Technologies is a medical aesthetic company, offering a range of aesthetics and specialized cosmetic products & devices. Its product range includes domestically and internationally manufactured products (Swyada, Tubelite, Etreluxe, Exoluxe, Etreclaire, etc.) and imported brands from countries like Korea, Spain, Italy, and Austria. The company supplies its products to dermatologists, plastic surgeons, and aesthetic physicians who then sell these products to their end consumers. As of March 31, 2025, it has a total of 154 Stock Keeping Units (SKUs) with 60 own brands and 94 imported brands.
Min Investment
₹115200
Price Range
₹68.00-72.00
Issue Size
₹25.64 Cr
IPO Type
NSE SME
Key Metrics
Check Live GMP
Face Value
₹10
EPS
6.13
P/E Ratio
11.75
RoNW
33.81%
ROE
33.81%
Debt to Equity
0.98
Timeline
IPO Opens
20 Jun
IPO Closes
24 Jun
Allotment
25 Jun
Listing
27 Jun
IPO Objectives
- Funding working capital requirements of the Company.
- General corporate purposes.
Strengths
- Experienced Management & Leadership Team with over 3 decades of experience in the industry.
- Diversified Product Base with 154 SKUs, including 60 own brands and 94 imported brands, catering to various aesthetic and cosmetic needs.
- Diversified Customer Base, supplying products to dermatologists, plastic surgeons, and aesthetic physicians, reducing reliance on a few clients (top 10 customers contributed only 10.96% of revenue in FY24).
- Pan India reach through a consignment sales partner and a dedicated team of over 90 sales and service engineers across 15 Indian states.
- Strong Financial Growth with revenue increasing by 33% and PAT surging by 110% between FY24 and FY25.
- Presence in a Niche & Growing Sector, the aesthetic medical segment, which is experiencing rising demand in both metros and Tier-II cities.
- Attractive Financial Ratios, including a high RoNW of 33.81% and a healthy EBITDA Margin of 15.81% (FY25).
Weaknesses
- Heavy reliance on imported third-party manufactured brands (62.28% of revenue in FY25), leading to potential exposure to supply chain disruptions and intellectual property leakage risks for own brands.
- Exposure to raw material and transportation cost volatility, which can impact profitability.
- Geographic concentration of revenue, particularly in Maharashtra and Karnataka, increasing location-specific business risks.
- Dependency on third-party agents for storage and distribution, which could lead to operational risks if these agreements are not performed adequately.
- Working capital-intensive business with rising receivables (Debtor Days of 166 days in FY25), which can strain cash flow.
- Intense competition from both domestic and international pump manufacturers in the aesthetic and cosmetic medical segment.
Financial Performance
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹ Cr.) | 51.85 | 34.01 | 23.23 |
| Revenue (₹ Cr.) | 61.76 | 46.27 | 32.88 |
| PAT (₹ Cr.) | 6.04 | 2.87 | 2.15 |
| Net Worth (₹ Cr.) | 23.2 | 12.53 | 9.66 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|
Subscription Details
Daily Bids Status
| Date | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0.33x | 0.33x | 3.51x |
| NII | 0.59x | 0.66x | 1.48x |
| RII | 0.31x | 0.89x | 1.91x |
| Total | 0.37x | 0.68x | 2.27x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 7,12,000 | 24,96,000 | 17.97 |
| NII | 5,36,000 | 7,93,600 | 5.71 |
| RII | 12,48,000 | 23,80,800 | 17.14 |
| Total | 24,96,000 | 56,70,400 | 40.83 |
Company Details
- 801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai, Maharashtra-400069, India
- +91 84528 44024
- companysecretary@aakaarmedical.in
- https://aakaarmedical.in/
Registrar Details
- Bigshare Services Pvt Ltd
- +91-22-6263 8200
- ipo@bigshareonline.com
- https://ipo.bigshareonline.com/IPO_Status.html